Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT0003X Phase I/II Study in Parkinson's Disease
TCTR20250401007Phase 2Recruiting
- Sponsor
- Interpharma
- Start
- Jan 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GT0003X in Parkinson's disease (PD), sponsored by Interpharma. Started Jan 2026; status: recruiting.
02
Drugs
GT0003X
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on TCTR20250401007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250401007.